Company news
Immutep Ltd (ASX:IMM) news
Immutep Ltd news releases on 6ix. Latest, Sep 30, 2026: Immutep Receives ~A$0.86 Million R&D Tax Incentive
Press releases & updates
Immutep Receives ~A$0.86 Million R&D Tax Incentive
September 30, 2026
Immutep : Receives ~A$0.86 Million R&D Tax Incentive
September 29, 2026
Change to American Depositary Share Ratio
September 21, 2026
Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
September 11, 2026
Immutep Outlines Focused Development Strategy for Efti
September 10, 2026
S&P DJI Announces September 2026 Quarterly Rebalance
September 4, 2026
Appendix 4E & 2026 Full Year Statutory Accounts
August 30, 2026
Immutep Quarterly Activities Report Q4 FY26
July 30, 2026
Immutep : Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
July 23, 2026
Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor
July 14, 2026
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
July 12, 2026
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy
July 6, 2026
Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients
May 28, 2026
Immutep : Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients
May 27, 2026
Immutep Receives Nasdaq Notice of Bid Price Deficiency
April 30, 2026
Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
April 22, 2026
Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma
April 15, 2026
Immutep receives FDA ODD for Efti in Soft Tissue Sarcoma
April 14, 2026
Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases
March 19, 2026
Update on Phase I Study of IMP761 for Autoimmune Diseases
March 18, 2026
TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
March 13, 2026
TACTI-004 to be discontinued following futility analysis
March 12, 2026
Reinstatement to Quotation
March 12, 2026
Suspension from Quotation
March 10, 2026
Trading Halt
March 6, 2026
Half Yearly Report and Accounts
February 24, 2026
Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
February 6, 2026
Immutep Achieves 50% Enrolment in Global TACTI-004-1L NSCLC
February 5, 2026
Immutep Quarterly Activities Report Q2 FY26
January 29, 2026
Immutep Quarterly Activities Report and Appendix 4C
January 29, 2026
Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study
December 22, 2025
Positive Update on IMP761 Phase 1
December 21, 2025
Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace
December 16, 2025
TACTI-004 phase III trial enrolment continues at robust pace
December 15, 2025
Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
December 8, 2025
Immutep enters into Strategic Collaboration with Dr. Reddy's
December 8, 2025
Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium
December 2, 2025
New data presentation from AIPAC-003 Phase II for SABCS
December 1, 2025
Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025
November 13, 2025
EFTISARC-NEO Phase II results presented at CTOS 2025
November 12, 2025
Immutep Receives A$4.6 million R&D Tax Incentive from French Government
November 3, 2025
Immutep Receives A$4.6 million French R&D Tax Incentive
November 2, 2025
Immutep Quarterly Activities Report Q1 FY26
October 29, 2025
Primary Endpoint Met in STS Trial - presented at ESMO 2025
October 19, 2025
Improved ORR in First Line NSCLC - presented at ESMO 2025
October 19, 2025
Immutep Announces Successful Completion of FDA Project Optimus Requirements
October 13, 2025
Successful Completion of FDA Project Optimus Requirements
October 12, 2025
Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer
October 9, 2025
TACTI-004 (KEYNOTE-F91) Phase 3 update in First Line NSCLC
October 8, 2025
Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti
September 22, 2025